Company profile
TG Therapeutics, Inc.
NASDAQ: TGTX · Healthcare · Biotechnology
#194 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
72BFH 86DQ 55GM 62SS 80
v0.1 · 65/100 weight · provisional
↑ net margin, return on equity · ↓ growth stability, disclosure history
Methodology →Revenue TTM
$700.3M
Rev growth YoY (TTM)
+81.3%
Net income (FY)
$447.2M
Employees
399
as of 2026-08-06
Market cap
$7.6B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$616.3M$616.3M2025
Net income$447.2M$447.2M2025
Operating income$123.3M$123.3M2025
Total assets$1.1B$1.1B2025
Liabilities$415.2M$415.2M2025
Equity$648.0M$648.0M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY23
FY23
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product98%
Royalty1%
Other Revenue1%
License Revenue0%
By geography
Not disclosed.
The read
What is TG Therapeutics, Inc.’s revenue?
TG Therapeutics, Inc. booked $616.3M in FY2025 revenue, growing 87% year over year — faster than most Healthcare companies we track, at a 72.6% net margin.
Peers · Healthcare
Doximity, Inc.73B10x Genomics, Inc.67BAxsome Therapeutics, Inc.59COPKO Health, Inc.74BInsmed Incorporated66BTransMedics Group, Inc.77B+Key facts
CEOMichael S. Weiss
SectorHealthcare
IndustryBiotechnology
HeadquartersMorrisville, NY
ExchangeNASDAQ: TGTX
Employees399
IPO date2010-05-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.